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AIT: Allergen immunotherapy
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EEC: Environmental exposure chamber
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TNSS: Total nasal symptom score
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2 ZUBERBIER ET ALEnvironmental exposure chambers are currently already used in
phase 2, 3, and even 4 trials. Unfortunately, few chambers exist in
the world, and this makes it difficult to perform large, multicenter
clinical trials. The new Global Allergy and Asthma European
Network (GA2LEN) mobile exposure chamber is a step forward
because the mobility of the chamber makes it convenient for
patients to participate in clinical testing.
Objective: This study was made to validate the reproducibility,
sensitivity, and specificity of the results obtained in the new
GA2LEN chamber.
Methods: Seventy-two adult patients (19-61 years old) with
allergic rhinitis with or without asthma caused by grass pollen
were included in different clinical validation tests. Total
symptom scores and total nasal symptom scores were recorded
at time zero (0) and every 10 minutes during exposures, along
with nasal and respiratory parameters.
Results: Exposure tests confirmed the reproducibility between
subsequent runs and the sensitivity (P < .00001 vs patients
exposed to placebo) and specificity (very low score in nonallergic
subjects) in the GA2LEN chamber. No adverse reactions were
recorded during the tests.
Conclusions: The mobility of the GA2LEN chamber provides a
new, potentially effective, and safe way of generating reliable
data in allergy multicenter clinical trials. (J Allergy Clin
Immunol 2016;nnn:nnn-nnn.)
Key words: Allergy trial, environmental exposure chamber, valida-
tion, grasses, placebo, Global Allergy and Asthma European
Network (GA2LEN)
Field allergy clinical trials depend on natural pollen exposure
and are therefore biased by a number of factors, the most
important being the variability of the pollen seasons, the changing
environmental conditions, and the uncertainty in determining the
actual individual exposure.1-3 This is especially true in multi-
center trials, in which pollen counts and environmental conditions
can be very different from one site to another. These aspects are
well summarized by Bousquet et al.4 In multicenter studies there
is also a risk of excluding some patients from the final analysis
because of the lack of relevant pollen exposure in one area.5
These problems can be overcome by the use of environmental
exposure chambers (EECs).2,6,7 Currently, however, EECs are
accepted by the European Medicines Agency and US Food and
Drug Administration only for phase 2 dose-ranging studies,8 even
though the use of EEC facilitates proper control and standardization
of the quantitative allergen exposure. Further advantages include
shortening the time frame of the dose-finding process, avoiding
the confounding effects of rescue medications, and using smaller
numbers of subjects than would be required in natural exposure
studies.6 EECs have been previously used for evaluating the efficacy
of pharmacotherapies for seasonal allergic rhinitis,9-11 both in phase
2 and still ongoing in phase 3 and even phase 4 trials,12 and studies
have also used EECs in allergen immunotherapy (AIT) investiga-
tions.13-15 A recent position paper from the European Academy of
Allergy and Clinical Immunology states that ‘‘EEC is likely to be
a good option as an adjunct to natural exposure studies for phase 3
Randomized Controlled Trials’’ also in AIT studies.16
However, there are drawbacks to the existing stationary EECs.
Very few such facilities exist around the word,3 and this makes it
very difficult to perform multicenter clinical trials.7 The repro-
ducibility of allergen exposure and treatment outcomes betweendifferent EECs is also a potential problem.17 Furthermore, pollen
in the stationary EECs is reventilated by a strong airflow, prohib-
iting measurement of individual exposures or a placebo control
within a run and being potentially irritating for the eyes and nose.
TheGlobal Allergy andAsthma EuropeanNetwork (GA2LEN)
has developed a novel mobile EEC called the GA2LEN chamber
to overcome these problems. The new mobile GA2LEN chamber
has been technically and clinically validated according to current
needs and requirements, as described in the article by Rosner-
Friese et al.3METHODS
Technical validation
The GA2LEN chamber consists of 2 standard 24-feet-high cubic containers
forming a compound of 7.45 m3 4.90 m3 2.86 m. One container accommo-
dates an office and changing room (A), and the other (B) houses the test cham-
ber itself and the installations for air conditioning (Fig 1). When set up, the
containers are interlocked, forming an interconnected compound, allowing ac-
cess to the test chamber through the changing room. Even though theGA2LEN
chamber consists of 2 containers, it can be transported by a single truck equip-
ped with a crane. Minimal requirements are necessary for the onsite setup,
which requires only external electricity (or a generator), to ensure theGA2LEN
chamber can be operated at a maximumnumber of trial sites. The test chamber
can accommodate up to 9 patients plus a nurse or a doctor, providing chairs that
are recommended for a seating time of up to 12 hours, with adjustable footrests
and surfaces that can be sanitized. Each chair has its own tablet holder. The
chairs are at fixed positions but can be removed for full cleaning (Fig 2).
The airflow in the test chamber was designed to be as low as possible,
meaning not recognizable, at each seating position to not create any adverse
reactions because of airflow (eg, feeling of nasal obstruction or eye reddening)
but still create sufficient air exchange to keep CO2 and O2 at comfortable
levels. Nevertheless, the air conditioning installed allows the chamber temper-
ature to be adjustable from 158C to 358C, whereas relative humidity levels can
be set from 30% to 80% (noncondensing). Gas levels, namely oxygen, carbon
dioxide, carbon monoxide, and ozone, are constantly monitored and recorded.
The outside air is filtered by using a multistage filter system, removing more
than 99% of particles smaller than 1 mm (and all allergens) from the air.
Because of the air conditioning capability and the extensive insulation,
experiments can be performed at outside temperatures of 2108C to 358C,
whereas outside relative humidity can be handled from 20% to 80%. The test
chamber is monitored by cameras and microphones. This allows doctors and
nurses to also monitor the patients remotely throughout the test procedure
while being located in the office room of theGA2LEN chamber. If agreed to by
signed consent, visual and audio data are also recorded. These recordings can
be used to validate symptom scores, such as number of sneezes.
Because of the limited seating available in the exposure chamber, a fast
turnaround time, meaning the time from ending one test until being able to
start another test, is necessary to enable several test runs within a day. The
major issue contributing to the turnaround time is the necessity to run the
FIG 1. The GA2LEN mobile exposure chamber.
FIG 2. The GA2LEN mobile exposure chamber: interior layout. Numbers
refer to seats for patients.
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run. To reduce the cleaning time, the GA2LEN chamber is not flushed with
pollen, which would result in pollen sticking to every surface in the room,
including the ceiling and walls. In the GA2LEN chamber pollen is dispersed
only where the subjects are seated, and the chamber airflow is designed so
that no other surfaces can be reached by the pollen, except the subjects’ chairs,
tablet holders, the floor directly beneath the subjects, and the subjects them-
selves. Therefore the subjects are required towear clean-room apparel to mini-
mize the amount of pollen adhering to the patient when leaving the chamber.
Wearing clean-room apparel also prevents other aeroallergens from being
introduced into the chamber. The floor is laid out as a double flooring, and
therefore pollen reaching the floor will fall through a metal grid, which makes
up the upper floor. Pollen falling through the grid will then be either sucked
through the exhaust air outlet and then removed by filtering the air or will stick
to the lower surface. The airflow design in the chamber prevents the pollen
from refloating. Not only does this approach allow for faster back-to-backtesting, it also allows for individualized testing, especially for research pur-
poses, where there are smaller cohorts but multiple differently parametrized
exposures. The GA2LEN chamber dispersal system is designed to have a dedi-
cated particle dispersal unit (PDU) placed above each chair, with its nozzle
positioned in a way that the particle concentration in the breathable air of a pa-
tient seated underneath is constant in a distinct region. This region is thor-
oughly confined, so that the particles dispersed from 1 PDU are not able to
be inhaled by a patient at another seat.
The height of the chair is adjustedwhen a patient is seated, so that the nostrils
of the patient are at a defined level, which is called the calibrated exposure
height. Breathable air is defined as the 2 L of air surrounding the upper airway
organs during each breath intake. Because the patient can move around (not by
moving the chair but by moving the upper body), the breathable air is actually
defined as an ellipse of 40 cm3 30 cm around the nose andmouth at calibrated
exposure height. The PDU takes particles from a blister and disperses these
particles through a nozzle.A blister in this case ismade of 2 sealed stripeswith a
single-layer (height) particle line in between. Thewidth of the line is controlled
with narrowmargins in the blistering process. Before dispersal, each particle is
photographed and counted. Each image is stored for later quality assurance
tasks. Because of previous individually performed calibrations, the defined and
required particle concentration in the patient’s breathable air can be controlled
easilyby the speed atwhich theblister is emptied.APDUcangenerate a particle
concentration from 100 particles per cubic meter of breathable air up to 15,000
particles per cubic meter during a time frame of up to 8 hours.Clinical validation
Patients and methods. All tests were performed in Berlin,
Germany, outside the relevant pollen season by using Phleum pratense (Aller-
gon AB, €Angelholm, Sweden) as the grass species. Reproducibility tests were
also performed after the chamber had been disassembled and then transported
to Barcelona and back. Based on power analysis, altogether, 72 adult patients
(19-61 years), both male and female (40% and 60%, respectively), were
included in the different validation tests.
Inclusion criteria were a history of mild-to-moderate allergic rhinitis with or
without asthma caused by grass pollen for 2 or more years, a skin prick test
FIG 3. Comparison of response to 4000 and 8000 grass pollen grains/m3 exposure in allergic subjects
(n 5 16 patients).
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4 ZUBERBIER ET ALresponse of 3 mm or greater and/or an ImmunoCAP score of 2 or greater, and
FEV1 of 70% of predicted value or greater. Exclusion criteria included previous
treatmentwithAIT, treatmentwith systemic corticosteroidswithin the lastmonth,
treatmentwith antihistaminesor other drugswith antiallergicpropertieswithin the
last 3 days, and suspicion of pregnancy. Five control subjects were nonatopic.
Patients were exposed during different lengths of time (90, 120, and
240 minutes) to 2 different pollen concentrations (4000 and 8000 grass pollen
grains/m3) and placebo. Because concentrations of 4000 and 8000 grass pollen
grains/m3 produced comparable results (Fig 3), we report here only the out-
comes of exposure to 4000 grass pollen grains/m3.
Patients recorded eye (itching, foreign body sensation, redness, and
watering), nose (itching, sneezing, running, and blocked), and bronchial
(wheezing, shortness of breath, and cough) symptoms. For every symptom, a
score of 0 to 3 was applied (none, mild, moderate, and severe). The total
symptom score (TSS) is the sum of all 3 scores (ie, eye/nose/lung;
minimum 5 0 and maximum 5 36). The total nasal symptom score (TNSS)
is the sum of the 4 nasal symptoms (minimum 5 0 and maximum 5 12).
Subjective parameters were recorded at time zero (0) and every 30 minutes
during exposure. The visual analog scale (VAS) score, peak nasal inspiratory
flow (PNIF), and peak expiratory flow were also recorded before entering the
chamber, after acclimatization in the chamber (10-30 minutes, time zero), and
every 30 minutes during exposure.
Statistical methods. Primary analysis is based on the area under
the curve (AUC) of values based on the per-protocol population. The statistical
model is based on an assumption of data having a symmetric distribution
(optimally a Gaussian distribution), and hence the log AUC values are
expected to be better suited for analysis than the arithmetic AUC values. This
was confirmed by means of analysis. Because some AUC values are 0, log
(AUC11) values are used; an approximate back transformation from a log
(AUC11) value of y is presented as follows: x 5 (exp [y]21)/120, where x
corresponds to a slightly weighted average of TNSSs over the 13 time points
(time 0-120). Aggregated values are analyzed as the values of the logAUC120
calculated by using the traditional trapezoidal formula. The active effects are
estimated and tested by using a mixed analysis of covariance model in which
covariates include age, sex, baseline score, number of the run, and subjects. All
analyses are programmed with SAS version 9.3 (SAS Institute, Cary, NC).
Ethical conduct of the study. The study was approved by the
ethics committee of the University Hospital Charite, Berlin, and all patients
provided written informed consent according to the Helsinki declaration.RESULTS
Reproducibility
The reproducibility of symptoms evoked in the EEC is one of
the crucial points for clinical validation.3 Eighteen allergic sub-
jects were exposed 2 times in the mobile chambers to 4000 grass
pollen grains/m3 for 90 minutes at intervals of 1 to 5 weeks be-
tween visits. VAS scores and PNIFs were recorded every 30 mi-
nutes. For both VAS scores (average maximum score: first
visit5 2.34, second visit5 2.52) and PNIFs (average maximum
score: first visit5 136 L/min, second visit5 151 L/min), results
were comparable between the 2 exposures (Fig 4). There was no
change in pollen distribution and exposure observed after disas-
sembling, moving, and reassembling the chamber.Comparison between placebo and active run
A total of 101 subjects took part in a placebo and active
run. Seventy-seven subjects were exposed to 4000 grass pollen
grains/m3 for 120 minutes. Patients with active grass allergy
reached a mean 6 SEM maximum TSS of 5.2 6 0.4 and TNSS
of 3.8 6 0.2 at 70 minutes. By comparison, 24 placebo-treated
subjects reached ameanmaximumTSS of 2.66 0.4 at 70minutes
and TNSS of 1.7 6 0.3 at 70 minutes (Fig 5 for TNSS). The dif-
ferences between TSSs and TNSSs recorded after exposure for
120 minutes to 4000 grass pollen grains/m3 of grass and placebo
were highly significant (P <.00001). Significant differences were
also observed in PNIF values and in nasal secretion between
grass-exposed and placebo-exposed subjects (P < .0001).No symptoms in nonatopic subjects
The specificity of the EEC exposure was demonstrated in a test
in which 5 nonatopic subjects were exposed for 120 minutes to
4000 grass pollen grains/m3 and compared with 36 allergic pa-
tients. Subjects recorded TNSSs, ocular scores, and bronchial
FIG 4. Reproducibility of EEC challenges in subsequent exposures. Eighteen allergic subjects were exposed
2 times to 4000 grass pollen grains/m3 for 90 minutes at intervals of 1 to 5 weeks between visits. A, VAS
scores. B, PNIFs.
FIG 5. Comparison of response to grass pollen and placebo exposure in allergic subjects (grass pollen,
n 5 55; placebo, n 5 30). Exposure was 4000 grass pollen grains/m3 (P < .0001).
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ZUBERBIER ET AL 5scores every 10 minutes, according to the previously described
scoring system (minimum 5 0, maximum 5 36). None of the
nonatopic patients reached a TSS of 1 (Fig 6).No effect of priming
Six patients were exposed for 120 minutes to 4000 grass
pollen grains/m3 on 5 consecutive days. TSSs were recordedevery 10 minutes, and VAS scores were recorded every 30 mi-
nutes. No difference was detected in either outcome between
day 1 and day 5 (Fig 7).Plateau reached
Seventeen patients were subjected to a longer exposure of up to
240 minutes. A TSS and TNSS plateau was reached after
FIG 6. Comparison of response to grass pollen exposure in allergic subjects and nonallergic control
subjects (n 5 36 allergic subjects and 5 nonallergic control subjects). Exposure was 4000 grass pollen
grains/m3.
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6 ZUBERBIER ET AL70minutes, with a peak at 90minutes and no further increase at up
to 240 minutes. Average peak values at 90 minutes were 5.4
(minimum-maximum, 1-14) for TSSs and 4.1 (minimum-
maximum, 1-8) for TNSSs (Fig 8).Safety
All exposure tests were safe and well tolerated. No clinically
significant adverse reactions were observed during the EEC
exposure, and no rescue medication had to be provided. No late
reactions were reported after 24 hours.DISCUSSION
Clinical tests performed in the new GA2LEN mobile chamber
showed high sensitivity, specificity, and reproducibility. Allergic
patients had a highly significant response compared with patients
exposed to placebo, whereas nonallergic patients showed no
response in terms of TNSSs. VAS scores observed in our valida-
tion study indicate that patients included in this study could be
classified as having ‘‘mild-to-moderate rhinitis’’ according to
the Allergic Rhinitis and its Impact on Asthma Guidelines,18 as
stated by Bousquet et al.19 This is important because the differ-
ence from placebo is generally statistically less pronounced
than in severely affected patients.20 TNSSs observed in our study
are comparable with those reported by Hohlfeld et al21 with the
same scoring system and at the same pollen concentration.
A minimum placebo response was observed in the placebo-
exposed patients. This has been observed before,3 and it is well
known that the placebo effect is particularly relevant in allergy
trials.22,23To avoid subjective biases, we assessed the reproducibility in
the GA2LEN chamber with subjective and objective parameters,
VAS scores and PNIF values, in 2 subsequent visits.24 VAS scores
have been found to correlatewith disease severity and to detect the
variations of symptoms in patients with allergic rhinitis with high
sensitivity.25,26 PNIF measurement is a very effective tool for as-
sessing the severity of congestion in allergic rhinitis,27,28 and
nasal flow has also been evaluated by Krug et al24 for validation
of the Fraunhofer chamber. In our study both VAS scores and
PNIFs showed comparable results between the 2 subsequent ex-
posures. Similar results have been observed in the past with sta-
tionary chambers. Hohlfeld et al21 exposed 60 patients with
grass pollen allergy to 4000 grass pollen grains/m3 in the
Fraunhofer ECC on 2 occasions during the pollen season, with
2-week intervals. TNSSs were highly reproducible between the
2 exposures.21 Interestingly, VAS scores reported by Hohlfeld
et al21 at the end of a 4-hour exposure are comparable with VAS
scores observed in our study and were also highly reproducible.
Krug et al,24 still using the Fraunhofer ECC, found comparable
results between 5 consecutive exposures evaluating TNSSs, nasal
flow rate, nasal secretion, FEV1, and peak expiratory flow, with a
grass pollen concentration of 8000 grass pollen grains/m3 for
4 hours. In this study a significant but not clinically relevant
reduction was observed in the mean FEV1, indicating a priming
effect.21
All these results confirm that symptoms elicited in consecutive
exposures in the GA2LEN mobile chamber have the same repro-
ducibility of symptoms provoked in the classic stationary EECs.
In contrast to previous reports,3,24,29 we did not observe any prim-
ing effect, with objective end points in 6 patients challenged on 5
consecutive days. This can be due to either the small number of
FIG 7. No evidence of priming effect in 5 exposures in consecutive days (n5 6 patients). Exposure was 4000
grass pollen grains/m3.
FIG 8. No symptom increase after prolonged exposure (n 5 17 patients). Exposure was 4000 grass pollen
grains/m3.
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exposure compared with the study by Krug et al24 (2 vs 4 hours;
4000 vs 8000 grass pollen grains/m3) or to the lack of a seasonal
exposure, which has been deemed relevant in previous
publications.6,29One of the key questions regarding EECs is whether symptoms
evoked in the chambers are comparable with those observed
during seasonal real-life exposure.3,24,30 Two studies addressed
this particular point. Jacobs et al31 found a strong correlation be-
tween nasal and ocular symptoms reported during natural
J ALLERGY CLIN IMMUNOL
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Hohlfeld et al21 found no correlation between the TNSS
evoked at the end of a 4-hour grass pollen exposure in the
EEC and symptoms registered during the pollen season. How-
ever, a good correlation was found with the TNSS registered
24 hours after the challenge. The authors concluded that
TNSSs after 24 hours better reflect the late-phase reactions
occurring during natural pollen exposure.19 Correlation be-
tween the symptoms in the chamber and natural allergen
exposure suggests that EECs can be used as a surrogate for
the natural allergy season exposure in clinical trials.17 Field
pollen allergy clinical trials suffer from some biases, the
most important being the variability of the real allergen expo-
sure of every study site and every single subject included in
the studies.3,7 Seasonal and local variations (humidity, temper-
ature, local specific pollutants, and different concentrations of
major allergens in the pollen) can have a big influence on the
pollen counts and symptoms. Furthermore, real exposure
heavily depends on the lifestyle of the subjects (indoor/out-
door) and indoor environmental exposures.1,3
Another problem is the difficulty of correctly defining the
pollen season, with its peak and duration being very different
from one year to another and differing by locations.7
Furthermore, the classic inclusion criteria in clinical trials
(skin tests, allergen-specific IgE, and clinical history) are not
able to distinguish patients with different levels of symptoms,
leading to the inclusion of patients with very low symptom
scores, another possible bias cause.30,31 Screening in an EEC,
as done previously,6 could overcome this issue by guarantee-
ing minimal symptoms with exposure according to entry
criteria.1,2,17
For these reasons, although the European Medicines Agency
already accepts the use of provocation tests (nasal, bronchial,
conjunctival, or exposure chambers) for phase 2 and dose-finding
studies in AIT,8 the already mentioned European Academy of Al-
lergy and Clinical Immunology position paper on clinical out-
comes in AIT considers the EEC a promising vehicle for phase
3 clinical trials in AIT.16 Actually, a number of controlled phase
3 and 4 studies are ongoing with antiallergic drugs using exposure
chambers.12 Compared with traditional provocation tests, the
EEC allows testing of many patients at the same time in a more
natural way and, above all, records all of the elicited organ symp-
toms, as happens in natural exposure.
Furthermore, there are also important financial issues. The
high costs of drug development are mainly based on the costs
of the clinical trials, and shorter trials are needed. The novel
EEC technology has a potential to perform trials more
efficiently than field trials because less patients need to be
included under standardized conditions. Unfortunately, very
few such chambers exist in the world today, and compara-
bility studies of individual EEC facilities are lacking because
of the great geographic distances between individual pollen
chambers and the specific technical features of each EEC
facility.16,17
These issues make the required multicenter clinical studies
very difficult to perform. Thus the mobile GA2LEN chamber rep-
resents a unique and novel solution to explore the biology of dis-
eases of the airways and potential therapeutic interventions using
multiple clinical trial sites to ensure the diversity of populations
necessary to better define study end points.Clinical implications: EECs are increasingly used in allergy
studies but have some limitations. The use of a mobile exposure
chamber can represent an advantage in clinical studies of AIT
and pharmacotherapy.REFERENCES
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